Interpace Biosciences, Inc. (IDXG)
OTCMKTS: IDXG · Delayed Price · USD
1.500
+0.077 (5.45%)
Apr 26, 2024, 3:52 PM EDT - Market closed
Interpace Biosciences Revenue
In the year 2023, Interpace Biosciences had annual revenue of $40.21M with 26.31% growth. Revenue in the quarter ending December 31, 2023 was $10.28M with 23.42% year-over-year growth.
Revenue (ttm)
$40.21M
Revenue Growth
+10.94%
P/S Ratio
0.16
Revenue / Employee
$372,343
Employees
108
Market Cap
6.56M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 40.21M | 8.38M | 26.31% |
Dec 31, 2022 | 31.84M | -9.48M | -22.94% |
Dec 31, 2021 | 41.31M | 8.92M | 27.52% |
Dec 31, 2020 | 32.40M | 8.32M | 34.55% |
Dec 31, 2019 | 24.08M | 2.18M | 9.97% |
Dec 31, 2018 | 21.90M | 6.00M | 37.74% |
Dec 31, 2017 | 15.90M | 2.81M | 21.49% |
Dec 31, 2016 | 13.09M | 3.65M | 38.73% |
Dec 31, 2015 | 9.43M | -110.50M | -92.14% |
Dec 31, 2014 | 119.94M | -30.91M | -20.49% |
Dec 31, 2013 | 150.84M | 23.94M | 18.87% |
Dec 31, 2012 | 126.90M | -30.39M | -19.32% |
Dec 31, 2011 | 157.29M | 12.64M | 8.74% |
Dec 31, 2010 | 144.65M | 59.78M | 70.44% |
Dec 31, 2009 | 84.87M | -27.66M | -24.58% |
Dec 31, 2008 | 112.53M | -4.60M | -3.93% |
Dec 31, 2007 | 117.13M | -122.11M | -51.04% |
Dec 31, 2006 | 239.24M | -80.17M | -25.10% |
Dec 31, 2005 | 319.42M | -45.03M | -12.36% |
Dec 31, 2004 | 364.44M | 47.00M | 14.80% |
Dec 31, 2003 | 317.45M | 33.44M | 11.77% |
Dec 31, 2002 | 284.01M | -412.57M | -59.23% |
Dec 31, 2001 | 696.58M | 279.71M | 67.10% |
Dec 31, 2000 | 416.88M | 241.98M | 138.35% |
Dec 31, 1999 | 174.90M | 73.80M | 73.00% |
Dec 31, 1998 | 101.10M | 46.40M | 84.83% |
Dec 31, 1997 | 54.70M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 85.16B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
IDXG News
- 7 weeks ago - Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results - GlobeNewsWire
- 6 months ago - Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results - GlobeNewsWire
- 9 months ago - Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results - GlobeNewsWire
- 10 months ago - Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement - GlobeNewsWire
- 11 months ago - Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023 - GlobeNewsWire
- 1 year ago - Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results - GlobeNewsWire
- 1 year ago - Interpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business Results - GlobeNewsWire
- 1 year ago - Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern - GlobeNewsWire